Joel Greenblatt

Joel Greenblatt

Last Update: 08-14-2017

Number of Stocks: 948
Number of New Stocks: 217

Total Value: $7,119 Mil
Q/Q Turnover: 33%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

Joel Greenblatt Watch

  • How to Invest in Gold in 2017 Part 5

    Gold for immdediate delivery witnessed a significant jump today. The precious metal increased by 1.08% on the London Bullion Market, up $12.2 per troy ounce to $1,146.80 per troy ounce from yesterday's closing price of $1,134.60.


      


  • 25 Questions With Tom Vilord of Vilord Wealth Advisors

    1. How and why did you get started investing? What is your background?


    I got started in the industry in 2000. I wanted to become a financial adviser because I wanted to learn how to research stocks like the guys on Wall Street. I wanted to learn what made Warren Buffett (Trades, Portfolio) so successful while most Americans failed to achieve success investing in the market. What did he know that the rest of us didn’t? After I passed my licensing exams, the company I was working for sent me to New York for three weeks of training. I thought this is when I was going to learn everything I needed to know to be a successful investor. Unfortunately, my first two weeks of training were nothing but sales training classes. The last week was training on all of the proprietary products. I was taught to be a salesperson. I learned absolutely nothing about how to invest money. And I was about to invest people's life savings. After a few years of not having a clue about what I was doing and having clients teach me stuff about the market, I started to self-teach myself. I bought every book I could read. I started taking personal one on one coaching courses, etc. I have been an adviser since 2000, but I have been an investor since 2005.

      


  • 25 Questions With Chris DeMuth Jr. of Rangeley Capital

    Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event-driven, value-oriented investment opportunities. Rangeley Capital and DeMuth's value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and DeMuth writes about them on StW.


    1. How and why did you get started investing? What is your background?

      


  • 18 Questions With John Huber of Saber Capital Management

    1. How and why did you get started investing? What is your background?


    I’ve always loved investing. My father was an engineer but was very active investing his savings in the stock market. By extension I became interested in stocks and investing relatively early on. But I came to the world of investment management unconventionally. I began my career in real estate, doing a variety of brokerage, investment and management activities in both residential and commercial real estate, and I established a few small partnerships with family members and friends to begin buying undervalued income-producing property. We bought residential properties as well as small multifamily properties.

      


  • Eldorado Gold Announces Approval of Revised Normal Course Issuer Bid by the TSX

    Eldorado Gold Corp. (NYSE:EGO) (TSX:ELD) announced on Monday that The Toronto Stock Exchange has approved its revised normal course issuer bid (NCIB), which allows the Canadian miner to buy back its own shares “through the facilities of the TSX and also through alternate Canadian trading systems.”


    The NCIB grants Eldorado permission to buy back a maximum volume of 2,081,168 of its ordinary shares, or about 0.30% of the total number of shares outstanding. The company had a total of 716,587,134 issued and outstanding shares as of Nov. 28.

      


  • AbbVie Files for Approval of Hepatitis C Treatment in the US

    AbbVie (NYSE:ABBV) announced today through PRNewswire that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its “investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).”


    The glecaprevir/pibrentasvir (G/P) regimen has been assessed on patients infected with chronic hepatitis C that have suffered kidney damage.

      


  • How to Invest in Gold in 2017

    With gold trending down, many investors interested in the industry are wondering which step to take. When the time comes, one of the ways to decide which gold mining stocks to invest in is analysing the characteristics of the gold industry and learning from the gurus’ moves.


    From Jan. 1 to Feb. 28, the price of gold on the London Bullion Market increased by 15.58%, as shown by the picture below that reports the following five sub-periods characterized by different trends in the gold price since the beginning of the year.

      


  • CEO of Intrexon Invests in Company

    Randal Kirk (Insider Trades), CEO and 10% owner of Intrexon Corp. (XON), purchased 34,606 shares on Dec. 13. The price per share was $28.90 for a total transaction of $1,000,113.


    Intrexon uses synthetic biology to create environmentally responsible products that meet the needs of the growing world population. The company has a market cap of $3.37 billion.

      


  • Watchlist Wednesday: Top 5 Magic Formula Stocks

    In this edition of Watchlist Wednesday, these are the top five stocks qualifying for the Magic Formula stock screen.


    This screen is influenced by the strategy discussed by Joel Greenblatt (Trades, Portfolio) in the book, "The Little Book That Still Beats the Market."

      


  • Joel Greenblatt More Than Doubles Home Depot Stake

    Guru Joel Greenblatt (Trades, Portfolio) more than doubled his stake in The Home Depot (NYSE:HD) during the third quarter, adding 345,905 shares of the company at an average price of $133.26 per share.


    The trade had a 0.58% impact on Greenblatt's portfolio. He owns 590,129 shares of the company.

      


  • Whole Foods Market Keeps Getting Cheaper

    Whole Foods Market's (NASDAQ:WFM) position has 200% growth potential from this price in the next decade, making it worth the risk. Let me start with the financials.


    Revenue is up 138% since 2007 totaling over $111 billion. That’s north of $35 million per store with gross margins at 34%.

      


  • Transplant Patients Show Improvement With Imbruvica

    AbbVie Inc. (NYSE:ABBV) announced Tuesday through PR Newswire that results indicate ibrutinib (trade name Imbruvica), a type of chemotherapy drug for the treatment of patients suffering from “chronic graft-versus-host disease (cGVHD),” is effective and safe.


    Previously, these patients underwent a “systemic therapy” based on “high dose glucocorticoids” that were unsuccessful, the company said.

      


  • Pioneer Investments Continues to Buy Alibaba, 8 Others

    Pioneer Investments operates in wide areas of investment vehicles: mutual funds, single manager hedge funds, funds of hedge funds, structured products, segregated and managed accounts, institutional funds. In both the second and third quarters the guru bought shares in the following stocks:


    Targa Resources Corp. (TRGP)

      


  • AbbVie's Imbruvica Has Favorable Response Rate Among Marginal Zone Lymphoma Patients

    On Dec. 5, AbbVie Inc. (NYSE:ABBV) announced through PR Newswire the results regarding whether ibrutinib (Imbruvica), a type of chemotherapy drug for the treatment of patients suffering from relapsed / refractory marginal zone lymphoma (MZL), is effective and safe.


    Marginal zone lymphoma belongs to the family of slow-growing non-Hodgkin's lymphomas. Extranodal MZLs generally occur outside the lymph nodes and involve the mucosa-associated lymphoid tissue of some organs, such as the stomach, the ocular adnexal (eyelid, orbital tissues), gut, salivary glands, bronchial tubes, skin and thyroid. Nodal marginal zone lymphomas involve the lymph nodes direcltly.

      


  • AbbVie, Johns Hopkins Unite for Cancer Research

    AbbVie Inc. (NYSE:ABBV)  and the Johns Hopkins University School of Medicine will conduct exploration, experimentation and discovery activities related to studying cancer, according to a five-year collaboration agreement.


    The worldwide biopharmaceutical company headquartered in Lake Bluff, Illinois, and Johns Hopkins University School of Medicine, located in Baltimore, announced through PR Newswire yesterday that the agreement encompasses the goal of targeting disparate fields of cancer research, including lung carcinoma, bowel cancer, breast, prostate and blood tumors.

      


  • Leukemia Treatment Achieves Promising Results

    Juno Therapeutics Inc. (NASDAQ:JUNO) communicated through the Business Wire on Dec. 3 that the results from the study undertaken in patients affected with lymphocytic leukemia (CLL) and treated with JCAR014 were promising.


    The results were presented by the biopharmaceutical company during the 58th American Society of Hematology (ASH) Annual Meeting.

      


  • Low-Priced Retail Stocks Gurus Shopped for Ahead of Holiday Season

    Those interested in out-of-favor stocks can’t look much further than retail. In a market routinely hitting all-time highs, the consumer discretionary sector’s 1.42% one-year return makes it the worst performing, second only to health care. But the statistics for apparel and department stores are much worse, and the upcoming crucial holiday season may not help.


    Belying the worsening picture for traditional retailers were a 0.8% rise in retail and food services sales in October and 2.9% increase for the 10 months ended in October, compared to the comparable periods. At the same August-October period, clothing and accessories eked out a 0.5% gain, and sales at in general merchandise including department stores were dropping 5.2%, according to data from the Census Bureau.

      


  • Smith & Wesson Reports Strong Quarter, but Stock Suffers Post Election

    Smith & Wesson (SWHC) released its second-quarter earnings for fiscal 2017 on Thursday.


    The well-known gun manufacturer reported an increase in profits and revenue. For the quarter, it reported a profit of $32.5 million, or 57 cents per share, up from $12.5 million, or 22 cents per share, a year earlier. The company reported revenue between $230 million and $240 million. Analysts forecasted $237.7 million. Sales climbed 63% to $233.5 million.

      


  • 9 Stocks Joel Greenblatt Continues to Buy

    Joel Greenblatt (Trades, Portfolio) is founder and managing partner of Gotham Asset Management LLC. In both the second and third quarters the guru bought shares in the following stocks:


    OraSure Technologies Inc. (OSUR)

      


  • Chuck Royce’s Top 3 New Holdings

    Chuck Royce (Trades, Portfolio) of Royce & Associates bought 51 new holdings in the third quarter. His top three new holdings are American Woodmark Corp. (NASDAQ:AMWD), Houlihan Lokey Inc. (NYSE:HLI) and Skechers (NYSE:SKX).


    Royce is the chairman and portfolio manager at Royce & Associates. His firm utilizes an active, bottom-up, risk-conscious and fundamental investment approach. It invests primarily in smaller companies and seeks great stocks that are trading for less than they estimate the company is worth.

      


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}